Doxa AB
STO:DOXA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.01
3.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Doxa AB
Accounts Receivables
Doxa AB
Accounts Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Doxa AB
STO:DOXA
|
Accounts Receivables
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Accounts Receivables
kr23m
|
CAGR 3-Years
54%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Accounts Receivables
kr188m
|
CAGR 3-Years
56%
|
CAGR 5-Years
29%
|
CAGR 10-Years
35%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Accounts Receivables
kr22.5m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Accounts Receivables
€53.8m
|
CAGR 3-Years
24%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Accounts Receivables
kr1.4m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
Doxa AB
Glance View
Doxa AB engages in the development, manufacture, and commercialization of bioceramic dental products. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2014-04-07. The firm develops, manufactures and commercializes products based upon its technology platform of calcium aluminate hydrate and bioactive ceramics. Activities are divided into the therapy areas of orthopedics and odontology. Research areas within orthopedics are methods for treating fractures resulting from osteoporosis, reconstructive orthopedics and coating of implants. Research areas within odontology are tooth restoration and implant fixation.
You don't have any saved screeners yet
